Search Results for "Vaccine Plus Flutamide Clical Trial Open In 2009"
Matching Channels
ATX-MS-1467 for patients with multiple sclerosis (MS)
ATX-MS-1467 is a novel treatment that was developed with the aim of working with the immune system to treat the underlying cause of disease rather than just treating the symptoms or suppressing the...
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of whi...
Matching News
Low-dose flutamide doesn't eliminate hepatotoxicity risk
NEW YORK (Reuters Health) - Low or ultralow doses of flutamide don't entirely eliminate the drug's potential for injuring the liver, researchers saw in a study of women with polycystic ovary syndr...
Latest HIV Vaccine Fails In The US, Government Stops Study
A study testing the latest experimental HIV vaccine has been stopped after an independent review board found that it did not prevent HIV infection and did not decrease the amount of HIV in the blood....
NIH halts trial of HIV prevention vaccine on lack of efficacy
NIH's National Institute of Allergy and Infectious Diseases (NIAID) discontinued the Phase IIb HVTN 505 trial to prevent HIV infection after an interim analysis showed a lack of efficacy of the vaccin...
Another HIV vaccine trial has been stopped early, after gay men given the vaccine were infected with the virus more than those given a placebo shot.
UPDATE 1-Pfizer's Prevenar 13 vaccine meets trial goal
Oct 4 (Reuters) - Pfizer Inc, which is seeking a wider use of its multi-billion dollar vaccine Prevnar, said a late-stage study of the Prevenar 13 vaccine met the main trial goal and the data will hel...
Sanofi Dengue Vaccine Suffers Mixed Trial Results, But High Unmet Need Could Help It Forward
The efficacy seen in Sanofi’s Phase IIb dengue vaccine trial was modest. At least one dengue vaccine expert thinks the pharma would stand a better chance if it developed the vaccine as one dose inst...
In HIV Vaccine Trial In Thailand, Competing Antibodies May Have Limited The Protection Achieved
Continuing analysis of an HIV vaccine trial undertaken in Thailand is yielding additional information about how immune responses were triggered and why the vaccine did not protect more people. In a st...
Competing antibodies may have limited the protection achieved in HIV vaccine trial in Thailand
Continuing analysis of an HIV vaccine trial undertaken in Thailand is yielding additional information about how immune responses were triggered and why the vaccine did not protect more people.
Matching PubMed Articles
Vaccination with the non-adjuvanted split-virion A/California/7/2009 influenza vaccine (pandemic H1N1 2009 vaccine) began in October 2009 in Japan. We studied how prior vaccination with a seasonal tri...
The novel influenza A(H1N1pdm09) virus emerged in North America in early 2009 and rapidly spread worldwide. In this study we report the efficacy of the live attenuated monovalent H1N1pdm09 vaccine and...
Involvement of Th2 cytokines in the mouse model of flutamide-induced acute liver injury.
Drug-induced liver injury is a growing concern for pharmaceutical companies and patients because numerous drugs have been linked to hepatotoxicity and it is the most common reason for a drug to be wit...
Antigenic stability of H1N1 pandemic vaccines correlates with vaccine strain.
In 2009 a novel H1N1 influenza virus emerged and spread rapidly. Soon after vaccine lots were released, however, the shelf life was revised downward due to an unexpected decrease in HA potency. In thi...
As 13-valent pneumococcal conjugate vaccine (PCV13) is introduced, children who began vaccination with 7-valent pneumococcal conjugate vaccine (PCV7) may complete their vaccination with PCV13. This op...
